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Sialic acids are important components of glycoproteins and glycolipids essential for cellular 
communication, infection, and metastasis. The importance of sialic acid biosynthesis in human 
physiology is well illustrated by the severe metabolic disorders in this pathway. However, 
the biological role of sialic acid catabolism in humans remains unclear. Here, we present 
evidence that sialic acid catabolism is important for heart and skeletal muscle function and 
development in humans and zebrafish. In two siblings, presenting with sialuria, exercise 
intolerance/muscle wasting, and cardiac symptoms in the brother, compound heterozygous 
mutations [chr1:182775324C>T (c.187C>T; p.Arg63Cys) and chr1:182772897A>G (c.133A>G; 
p.Asn45Asp)] were found in the N-acetylneuraminate pyruvate lyase gene (NPL). In vitro, 
NPL activity and sialic acid catabolism were affected, with a cell-type-specific reduction of 
N-acetyl mannosamine (ManNAc). A knockdown of NPL in zebrafish resulted in severe skeletal 
myopathy and cardiac edema, mimicking the human phenotype. The phenotype was rescued 
by expression of wild-type human NPL but not by the p.Arg63Cys or p.Asn45Asp mutants. 
Importantly, the myopathy phenotype in zebrafish embryos was rescued by treatment with the 
catabolic products of NPL: N-acetyl glucosamine (GlcNAc) and ManNAc; the latter also rescuing 
the cardiac phenotype. In conclusion, we provide the first report to our knowledge of a human 
defect in sialic acid catabolism, which implicates an important role of the sialic acid catabolic 
pathway in mammalian muscle physiology, and suggests opportunities for monosaccharide 
replacement therapy in human patients. 
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Introduction
Sialic acids, a group of  structurally diverse, negatively charged, 9-carbon-chain sugar compounds are found 
in humans, animals, and bacteria, most commonly as terminal sugars in oligosaccharides. Sialic acids are 
important for a variety of  biological functions including cell-cell interactions, bacterial and viral infections, 
and tumor metastasis (1).
Biosynthesis of  endogenous sialic acid occurs in the cytosol, starting from UDP-N-acetyl glu-
cosamine (UDP-GlcNAc). Epimerization and phosphorylation of  UDP-GlcNAc by the bifunctional 
enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) yields Man-
NAc-6-phosphate, which is converted to N-acetylneuraminic acid (Neu5Ac) by N-acetylneuraminic 
acid synthase (NANS) and N-acetylneuraminic acid phosphatase (NANP), respectively. Subsequently, 
Neu5Ac is activated in the nucleus by N-acylneuraminate cytidylyltransferase (CMAS) to form cyt-
idine-5-monophosphoneuraminic acid (CMP-Neu5Ac) (2). CMP-Neu5Ac is transported to the Gol-
gi apparatus by SLC35A1 (3) for sialylation of  glycoproteins and gangliosides catalyzed by specific 
sialyltransferases (4). Within the cytoplasm, CMP-Neu5Ac binds to GNE providing a negative feed-
back regulation of  de novo Neu5Ac synthesis. Free Neu5Ac is also generated by the lysosomal salvage 
pathway, where sialic acids are released from sialoglycoconjugates by neuraminidases 1, 3, and 4 (5, 
6). Neu5Ac is then transported to the cytosol by sialin, encoded by SLC17A5, for synthesis of  CMP-
Neu5Ac. Although the majority of  research on the biological function of  sialic acids has focused on 
the biosynthetic pathway, enzymes for Neu5Ac catabolism have been identified in humans and animals. 
Neuraminic acid pyruvate-lyase (NPL), also known as sialic acid aldolase (7), can act on Neu5Ac to 
form N-acetylmannosamine (ManNAc) and pyruvate. ManNAc can be converted to N-acetylglucos-
amine (GlcNAc) by N-acetylglucosamine 2-epimerase (RENBP) and subsequently phosphorylated to 
GlcNAc-6-phosphate for entry into the hexosamine biosynthesis pathway. How these 3 pathways, i.e., 
biosynthesis, lysosomal salvage, and catabolism, are regulated and how each of  them contributes to the 
levels of  Neu5Ac and its metabolites remains unclear.
Important lessons on the biological role of  Neu5Ac arose from genetic disorders (8). Two diseases 
caused by defects in CMP-Neu5Ac biosynthesis are known: GNE mutations result in an adult-onset myopa-
thy (MIM 605820), whereas patients with NANS deficiency (MIM 610442) show intellectual disability and 
skeletal dysplasia (9). Both defects are thought to be caused by reduced production of  CMP-Neu5Ac. Dras-
tically increased Neu5Ac in urine, sialic aciduria, has been associated with 2 genetic conditions. French-
type sialuria (MIM 269921) due to defective feedback inhibition of  GNE by CMP-Neu5Ac presents with a 
relatively mild lysosomal storage–like disorder. A defect in the lysosomal salvage pathway due to recessive 
mutations in SLC17A5 can result in a severe multisystem lysosomal storage disorder (MIM 269920) or a 
milder cognitive disease (Salla disease, MIM 604369). Although the clinical phenotypes of  these disorders 
are considerably different, progressive muscle involvement is present in GNE myopathy and as hypotonia 
in SLC17A5 deficiency. Heart involvement has been reported sporadically in both syndromes.
Here, we describe a human genetic defect in sialic acid catabolism due to biallelic mutations in NPL, 
resulting in sialic aciduria and a clinical phenotype of  progressive cardiac myopathy and mild skeletal 
myopathy. We demonstrate dysfunction of  the mutant NPL enzyme and a block in sialic acid catabolism 
and document a phenotype in a zebrafish NPL model that mimics the human clinical presentation. Fur-
thermore, we show that the muscle phenotype in the npl zebrafish model could be rescued by supplementa-
tion with the monosaccharide products of  the NPL reaction. Combined, our data indicate the importance 
of  the Neu5Ac catabolic pathway for human muscle physiology.
Results
A cause of  sialic aciduria with heart and skeletal muscle dysfunction. A 22-year-old male proband (P1.1) was a 
second child of  healthy nonconsanguineous Filipino parents. During the pregnancy, fetal arrhythmia (third 
degree heart block) with hydrops was diagnosed, and delivery was induced at 33 weeks gestation. At birth, 
the left ventricle was enlarged with normal output. Sensorineural hearing loss was also noticed. Subsequent-
ly he developed progressive dilated cardiomyopathy with left ventricular ejection fraction of  only 20%, 
which was complicated by cardiac arrest. At the age of  16 years, he demonstrated mild joint hypermobility, 
retrognathia, and thin musculature with a mild proximal myopathy in upper and lower limbs (MRC grade 
4/5). During metabolic analysis a marked increase in urinary sialic acid was identified. The patient’s older 
female sibling (P1.2), who refused clinical examination, has a history of  exercise intolerance and a mild 
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muscle weakness. She also has marked sialic aciduria. The levels of  urinary Neu5Ac were in the range of  
patients with Salla disease (Figure 1A); however, no accumulation of  Neu5Ac in fibroblasts could be detect-
ed (Figure 1B). In addition, no clinical resemblance was found with Salla disease or French-type sialuria. 
Metabolic investigations showed normal sialylation of  transferrin and apolipoprotein CIII (data not shown).
In searching for the genetic cause, trio (proband-mother-father) whole exome sequencing (WES) and 
prioritization of  genetic variants were performed as described in the Methods section (10). Rare, nonsyn-
onymous genetic variants were identified in 26 genes following different modes of  Mendelian inheritance 
(Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.122373DS1). Of these, only the 2 missense variants of  the NPL gene, involved in sialic acid catab-
olism, could be related to the sialic aciduria in our patients: chr1:182775324C>T (c.187C>T; p.Arg63Cys), 
NM_030769, with reported ExAC 4/121286 and gnomAD 7/277158 occurrence; and chr1:182772897A>G 
(c.133A>G; p.Asn45Asp), NM_030769, with reported ExAC 112/121088 and gnomAD 242/277152 
occurrence; Figure 1, C–E). Both variants were predicted to be damaging by SIFT (11) and Polyphen2 (12), 
with CADD scores of  34 and 21.4 (13), respectively. The same variants were found by Sanger sequencing 
in the affected sister with trans parental inheritance (Figure 1C). Aside from NPL, variants in the other 25 
genes were further excluded as candidate genes for sialic aciduria on the basis of  segregation analysis, patho-
genicity prediction score, mode of  inheritance, and/or known phenotype and gene functions (Supplemental 
Table 1). No additional patients with causative mutations in NPL could be identified in the exome data of  a 
multicenter cohort of  approximately 2,000 patients with neuromuscular disease.
p.Arg63Cys and p.Asn45Asp mutations affect enzymatic activity and stability of  NPL. To study the 
effect of  mutations, wild-type (WT) or mutant NPL variants containing a C-terminal DYK tag were 
expressed in HEK293T cells. To verify equal transfection efficiencies, the cells were cotransfected 
with the pCMV-HGSNAT-GFP plasmid (14). Forty-eight hours after transfection, NPL activity in the 
cell homogenates was measured against Neu5Ac, N-glycolylneuraminic acid (Neu5Gc), or 2-keto-3- 
deoxy-D-glycero-D-galacto-nononic acid (KDN), as described by Brunetti et al. (15). Cells transfected 
with the WT NPL plasmid showed an approximately 16-fold increase in Neu5Ac lyase activity as 
compared with untransfected cells. The activity in the cells expressing the p.Asn45Asp and p.Arg-
63Cys NPL mutants was significantly lower, approximately 30% and approximately 6% of  the WT, 
respectively (Figure 2A). In addition, the p.Asn45Asp NPL mutant had 3.2-fold increased Km and 
2.6-fold decreased Vmax values as compared with the WT enzyme (Figure 2B), suggesting that the 
mutation decreased the enzyme affinity for Neu5Ac approximately 8-fold, most probably affecting 
its function inside the cell. The activity of  the WT NPL against Neu5Gc was 5-fold lower than that 
against Neu5Ac (Supplemental Figure 1) and below the detection limit for the mutants. Neither WT 
enzyme nor mutants had any activity against KDN (data not shown).
The protein expression levels of  the WT NPL and its mutants were tested by Western blot using anti-
DYK tag antibodies that detected a single 36-kDa protein band with expected size. We found (Figure 2C) 
that the expression level of  the p.Asn45Asp NPL mutant, although significantly lower then that of  the WT 
NPL, was reduced only to approximately 60% ± 13%, suggesting that the mutation mainly affects the enzy-
matic activity. The expression level of  the p.Arg63Cys NPL mutant was reduced to approximately 25% ± 
4% of  the WT NPL, suggesting that the mutation interferes with expression and/or stability of  the enzyme. 
To test this directly, we studied the stability of  the WT NPL and its mutants by nonradioactive pulse-chase 
in which we blocked de novo protein synthesis in the transfected cells and measured intensity of  the NPL 
protein band at 2, 4, 6, 18, and 24 hours by Western blot. Our results (Figure 2D) show that the cellular 
half-life of  p.Asn45Asp and p.Arg63Cys NPL mutants (19.6 and 7.3 hours, respectively) is significantly 
lower than that of  the WT enzyme (161 hours).
p.Arg63Cys and p.Asn45Asp mutations alter Neu5Ac metabolism in patient tissues. A potential dysfunction 
of  NPL was studied by incubating homogenates of  P1.1’s fibroblasts and red blood cells (RBCs) with 
Neu5Ac. Quantitative mass spectrometric analysis showed a time-dependent decrease of  Neu5Ac in con-
trol RBCs. In contrast, RBCs of  P1.1 from 2 independent sampling dates did not show any catabolism of  
Neu5Ac (Figure 3A). No activity was detected in human control fibroblasts, which is in agreement with 
the absence of  sialic acid accumulation in the patient’s cultured fibroblasts. The analysis of  free Neu5Ac 
in the patient’s RBCs revealed an accumulation of  approximately 50- to 100-fold as compared with control 
cells (262.5 pmol/mg protein, reference range 2.5–5.8), consistent with the catabolic dysfunction of  NPL 
in RBCs (Supplemental Table 2).
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Metabolomics analysis (16) confirmed free Neu5Ac accumulation in urine and plasma. To further 
investigate the effect of  NPL deficiency on the downstream Neu5Ac metabolites, we first studied a pos-
sible reduction of  ManNAc levels in body fluids. Levels of  ManNAc were low in urine and plasma of  
both patient P1.1 and controls (data not shown). We then analyzed the intracellular levels of  ManNAc, 
ManNAc-6-phosphate, and Neu5Ac via a mass spectrometric method adapted from Buescher et al. (17). 
A clear reduction of  ManNAc and ManNAc-6-phosphate levels was observed in patient RBCs, but not in 
fibroblasts (Figure 3, B–G), indicating that the levels of  Neu5Ac, ManNAc, and ManNAc-6-phosphate 
are strongly dependent on NPL only in specific cell types.
 Figure 1. NPL deficiency and identification of NPL biallelic missense varants in NPL. (A) Sialic aciduria was determined by quantification of the levels of urinary 
Neu5Ac excretion and compared with known causes of sialic aciduria. For NPL patient 1, two samples were analyzed at around age 20 years. Salla refers to both 
ISSD at a very young age and Salla disease. (B) As part of the diagnostics of sialic aciduria, quantification of Neu5Ac levels in fibroblasts was performed, showing 
normal levels in contrast to known causes (all n = 1). (C) Whole exome sequencing, covering 37.8× for the subject, 30.4× for the mother, and 27.5× for the father, 
to identify NPL missense varants. (D) Comparison of the amino acid sequences of NPL in human (Q9BXD5.1), zebrafish (CAP19481.1), mouse (NP_083025.1), dog 
(XP_005622466.1), chicken (NP_001026731.1, Xenopus (NP_001011207.1), and alpaca (XP_015101171.1), as well as 2 mutants. Conserved asparagine (N) and arginine 
(R) are highlighted. Mutations are shown in red. (E) Biallelic NPL variants c.133A>G (p.Asn45Asp) and c.187C>T (p.Arg63Cys) (reference transcript NM_030769) are 
mapped on NPL exon 2 and 3, respectively.
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Altogether, our data clearly demonstrate the deleterious impact of  the compound heterozygous 
variants in NPL as detected in both patients, causing impairment of  Neu5Ac catabolism resulting in 
its accumulation and free sialic aciduria.
Npl knockdown in zebrafish mimics the human phenotype and can be rescued with human NPL but not its 
p.Arg63Cys and p.Asn45Asp mutants. Given that the expression pattern of  npl in zebrafish is unknown, we 
performed in situ hybridization on zebrafish embryos at different developmental stages. We found that 
npl is already expressed in 1-cell-stage embryos, indicating maternal contribution (Figure 4A). In addi-
tion, npl is strongly expressed in somites and embryonic muscle in 18-somite-stage embryos (Figure 4A). 
At 24 hours postfertilization (hpf), npl presents a more restricted expression pattern, with higher expres-
sion in the head (Supplemental Figure 2). Expression of  npl in the intestine is also evident at 48 hpf, 
Figure 2. p.Asn45Asp and p.Arg63Cys mutations affect enzymatic activity and expression and/or stability of the NPL protein. (A) Cultured HEK293T 
cells cotransfected with plasmids encoding cDNA of the wild-type (WT) human NPL or its p.Arg63Cys and p.Asn45Asp mutants containing a C-terminal 
DYK tag and pCMV-HGSNAT-GFP plasmid encoding human acetyl-CoA: α-glucosaminide N-acetyltransferase (HGSNAT). Forty-eight hours after trans-
fection, the cells were harvested and the enzymatic NPL and HGSNAT activities were measured in cell homogenates. (B) The reaction rate of Neu5Ac 
hydrolysis by the WT NPL and the p.Asn45Asp NPL mutant were measured at different initial concentrations of the substrate to calculate the Km and 
Vmax values for the WT and mutant enzyme. (C) The protein levels of WT NPL and its mutants were measured by Western blot using antibodies against 
the DYK tag. Panels show representative images of 3 independent experiments. The bar graph shows intensities of the DYK cross-reactive protein 
bands (means ± SD of the values from 3 independent experiments) measured with ImageJ software and normalized to the intensities of the control 
HGSNAT protein band stained with anti-HGSNAT antibody. (D) Stability of WT NPL protein and its mutants was measured by nonradioactive pulse-
chase experiment. HEK293T cells expressing WT or mutant NPL were treated with 7 μM cycloheximide to inhibit de novo protein synthesis, chased 2, 
4, 6, 18, and 24 hours, and analyzed by Western blot to measure intensity of the NPL protein band (DYK tag). Panels show representative images of 3 
independent experiments; 20 and 60 μg of protein was loaded per well for the cells transfected with the WT and mutant plasmids, respectively. Bands 
representing mature NPL (NPLm) and its precursor (NPLp) are marked. The graph shows intensities of the DYK cross-reactive protein bands (means ± 
SD of the values from 3 independent experiments) measured with ImageJ software. Table shows half-life of WT and mutant NPL protein (hours) calcu-
lated using 1-phase decay nonlinear regression. *P < 0.05, **P < 0.01, ***P < 0.001 versus WT by 1- and 2-way ANOVA.
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as well as at 3 and 4 days postfertilization (dpf). In addition, npl is detected in facial musculature and the 
limb bud at 3 and 4 dpf  (Supplemental Figure 2). Hybridization with a sense probe rendered a negligible 
signal (Figure 4A), confirming the specificity of  the npl anti-sense probe. For comparison, we also per-
formed expression analysis of  the NPL gene in cDNA pools of  human fetal and adult tissues. Highest 
expression was observed in spleen, while other tissues, including heart and skeletal muscle, showed 
relatively similar expression levels (data not shown). Overall, the expression pattern of  npl is consistent 
with a possible function in muscle development.
Figure 3. Neu5Ac catabolism and NPL metab-
olites in patient cells. (A) Neu5Ac catabolism 
was analyzed in patient RBCs by incubation of 
control or NPL patient 1–derived RBCs with 500 
μM Neu5Ac. Neu5Ac levels after different time 
points were quantified by mass spectrometry. 
Metabolites of the NPL reaction were analyzed 
in RBCs (B–D) and fibroblasts (E–G). Dot plots 
represent peak areas of HexNAc (B and E), 
ManNAc-6-phosphate (C and F), and Neu5Ac 
(D and G), normalized against the sum of AMP, 
ADP, and ATP. Separate dots represent technical 
replicates. Separate samples represent inde-
pendent drawings of blood (patient RBCs) or 
different donors (ctrl RBCs).
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To determine whether deficiency of npl affects muscle development and structure, we knocked down npl 
gene expression in zebrafish embryos by injecting a morpholino oligonucleotide targeting the ATG codon 
(npl-atg MO) to block translation. npl morphants, but not embryos injected with a standard control morpholi-
no (Cont MO), were found to have mild pericardial edema, curved tail, and somite disorganization (Figure 
4B). Western blotting (Figure 4C) and NPL enzymatic assay (Supplemental Figure 3) confirmed efficient npl 
knockdown in morphants. To assess somite morphology and muscle fiber organization, we performed con-
focal imaging on 48-hpf morphants and Cont MO–injected embryos stained with phalloidin, which reveals 
actin filaments. This analysis demonstrated abnormal somite morphology with disarrayed muscle fibers in npl 
morphants (Figure 4D). In situ hybridization for myod, a skeletal muscle marker (18), confirmed abnormal 
somite morphology in npl morphants at 24 hpf and 48 hpf (Supplemental Figure 4). In addition, myod staining 
revealed absence of ocular and facial muscles in morphants at 48 hpf.
To further validate the functional rescue of  the muscle phenotype, we studied the locomotion behavior 
of  2-dpf  zebrafish larvae by a touch response. As shown in Figure 5, A and B, npl-atg MO–injected zebraf-
ish larvae demonstrate decreased motor behavior in response to touch, in terms of  total distance moved 
and maximum velocity swam. Coinjection of  WT mRNA in the npl morphants or supply of  ManNAc in 
embryo water significantly improves swim behavior of  the npl-atg MO–injected larvae (Figure 5, A and B).
A recent study demonstrated that GNE myopathy is associated with muscle oxidative stress in 
humans and mice (19). To study the role of  oxidative stress in npl-associated myopathy, we analyzed 
reactive oxygen species (ROS) levels in zebrafish trunk muscles in vivo (Figure 5C). The npl-atg mor-
phants showed a 2-fold increase in ROS levels in the trunk muscles compared with the embryos injected 
with Cont MO. In contrast, coinjection of  npl-atg MO with WT human NPL mRNA significantly low-
ered ROS levels. Furthermore, incubation of  npl-atg morphants with ManNAc also rescued and lowered 
ROS to control levels (Figure 5D).
To further confirm the involvement of  npl in muscle development, we knocked down npl using a splic-
ing morpholino targeting the exon 4/intron 4 boundary (npl-sp MO). As expected, morphants displayed 
abnormal somite morphology along with disarrayed muscle fibers, and pericardial edema (Supplemental 
Figure 5). Reverse transcription PCR (RT-PCR) on Cont MO produced a 260-bp band corresponding to the 
length of  properly spliced exons 3, 4, and 5. In contrast, an enlarged product consistent with retention of  
intron 4 was detected in npl-sp MO morphants (Supplemental Figure 5, A and C).
Pericardial edema is often a sign of  cardiac dysfunction. Therefore, we analyzed heart morphology in 
npl morphants. Epifluorescence images of  embryos carrying the cmlc2:GFP transgene, which labels cardio-
myocytes, revealed abnormal looping of  the heart tube in the npl morphants (Figure 4E).
To exclude potential off-target effects of  the npl-atg MO, we evaluated whether coinjection with human 
NPL mRNA rescues the phenotype in morphants. In both NPL mRNA–injected and control morphants 
we assessed somite morphology and muscle fiber arrangement. As expected, injection of  the npl-atg MO, 
but not the Cont MO, resulted in a drastic decrease in the percentage of  embryos with normal somite mor-
phology. Sixty-six percent of  embryos injected with the npl-atg MO (Figure 6, C and D), and less then 1% 
of  embryos injected with Cont MO, had abnormal somite morphology (Figure 6, A and B, and Figure 7). 
In contrast, coinjection of  npl-atg MO with WT human NPL mRNA significantly increased the percentage 
of  embryos with normal muscle morphology (77%; Figure 6, E and F, and Figure 7), suggesting that the 
injected human NPL mRNA rescued the npl-atg MO phenotype in zebrafish.
To further demonstrate that NPL p.Asn45Asp and p.Arg63Cys are disease-causing mutations, we syn-
thesized mutant NPL minigenes carrying single or double (p.Asn45Asp plus p.Arg63Cys) mutations and 
generated mutant mRNA by in vitro transcription, and performed mRNA rescue experiments (Figure 6, 
A–T, and Figure 7). Injection of  double-mutant NPL mRNA did not rescue the npl-atg MO–induced phe-
notype, as 72% of  embryos showed myopathy (Figure 6, I and J, and Figure 7). Injection of  p.Asn45Asp 
or p.Arg63Cys mutant mRNA also yielded at least 42% of  embryos with myopathy in both cases (Figure 
6, M, N, Q, and R, and Figure 7), providing additional indication that p.Asn45Asp and p.Arg63Cys are 
disease-causing mutations.
NPL-myopathy is improved by monosaccharide replacement in zebrafish, offering options for therapeutic intervention. 
In view of the suggested catabolic function of  NPL, we hypothesized that the downstream monosaccharide 
products of  the NPL reaction, ManNAc and/or GlcNAc, could rescue the npl morphant phenotype. Embry-
os injected with Cont MO or npl-atg MO were treated with ManNAc, GlcNAc Neu5Ac, and control mono-
saccharides (D-galactose, D-mannose, or D-xylose) followed by analysis of  somite and heart morphology and 
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Figure 4. npl is essential for muscle 
development in zebrafish. (A) Whole-
mount in situ hybridization of npl on WT 
embryos using antisense and control 
sense probes. In situ hybridization 
showing npl expression (arrow) in 1-cell-
stage, indicating maternal expression, 
and 18 -somite embryos. npl is broadly 
expressed in embryos at the 18-somite 
stage. Arrows in lateral view point to 
somites in closeup. The experiment was 
repeated 3 times. Scale bars: 200 μm 
(left) and 250 μm (middle). (B) Lateral 
views of zebrafish embryos at 48 hours 
postfertilization (hpf) that were injected 
with control (Cont) and atg morpholi-
no (MO) oligonucleotides against npl 
(npl-atg). Severe somite disorganization 
and mild pericardial edema (boxes) were 
observed. Scale bar: 750 μm. (C) Western 
blot of NPL in Cont MO– and npl-atg 
MO–injected embryos; β-actin was used 
as loading control. (D) Confocal images 
of muscle fibers in somites (arrows) 
immunostained for phalloidin in Cont 
MO and npl atg MO. Scale bar: 50 μm. (E) 
Epifluorescence images of the heart in 
cmlc2:GFP transgenics at 48 hpf injected 
with Cont MO and npl-atg MO. Boxes 
delimit close-up views of hearts. Scale 
bars: 100 μm (left) and 25 μm (right).
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Figure 5. Rescue of zebrafish npl deficiency in morphant embryos by NPL mRNA or ManNAc. (A) Behavior rescue in a touch response assay. Coin-
jection of WT mRNA or incubation in 800 μM ManNAc solution significantly improved swim behavior of npl-atg morphant larvae in terms of total 
distance moved, maximum velocity, and total time travelled. Error bars represent the standard deviation of 6–9 larvae. Significance was determined 
using a linear mixed-effects model with npl-atg MO injection conditions (fixed effect) and individual larvae (random effect), with Bonferroni’s 
post hoc test. (B) Representative paths swam in response to touch for groups of Cont MO, npl-atg MO, npl-atg MO/NPL WT mRNA, npl-atg MO/
ManNAc, and Cont MO/ManNAc zebrafish larvae. Videos are attached as supplemental materials. (C) Myopathy in npl morphants is associated with 
increased ROS levels in skeletal muscle. Increased fluorescence in npl mutants revealed by a ROS indicator is rescued by WT NPL mRNA injections 
or ManNAc treatment. (D) Quantification of fluorescence relative to Cont MO embryos in embryos injected with npl-atg MO, npl-atg MO coinjected 
with WT human (NPL mRNA WT), or npl-atg MO incubated with ManNAc. Bars represent the mean ± SE. n = 10–11 embryos per treatment. Sta-
tistical significance was determined using 1-way ANOVA with Bonferroni’s post hoc test assuming equal variance using GraphPad Prism software 
version 7. *P < 0.05, **P < 0.01, ***P < 0.001.
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muscle fiber arrangement. Incubation with ManNAc and GlcNAc resulted in a significant increase in the per-
centage of  embryos with normal somite morphology in npl-atg morphants (Figure 8, A, B, and G). ManNAc 
was the most efficient, with 88% of npl-atg MO embryos rescued (Figure 8, A and G), followed by GlcNAc 
with 72% rescue (Figure 8, B and G). Neu5Ac (sialic acid ) could also rescue the muscle phenotype to a lesser 
extent (46%, Figure 8, C and G), possibly attributable to the residual activity of  NPL, which allows increased 
production of  ManNAc upon feeding with Neu5Ac. Control monosaccharides did not provide any rescue 
of  the muscle phenotype (Figure 8, D–G). Furthermore, confocal imaging of  somites immunostained with 
phalloidin, and cmlc2:GFP transgenic embryos showed that incubation with ManNAc, and GlcNAc, and to a 
lesser extent with Neu5Ac, improved muscle fiber arrangement. Feeding with ManNAc but not with GlcNAc 
or Neu5Ac significantly improved heart looping studied by both stereo- and confocal microscopy (Figure 
9A–D). Furthermore, incubation of  npl-atg morphants with ManNAc demonstrated a rescued phenotype 
of  locomotion behavior deficit (Figure 5, A and B) and restored relatively normal ROS levels, comparable to 
controls (Figure 5, C and D). ManNAc also reestablished normal somite morphology and muscle fiber array 
in npl-sp MO morphants (Supplemental Figure 5D).
Discussion
Here, we report the first evidence to our knowledge for a physiological role of  sialic acid catabolism (Figure 
10) and its downstream metabolites ManNAc and GlcNAc in mammalian muscle physiology. Compound 
heterozygous missense variants were identified in NPL in human siblings, and shown to cause its dys-
function in vitro and in vivo. A biological role of  sialic acid catabolism independent from glycosylation 
of  proteins and lipids was demonstrated by the rescue of  the muscle and heart phenotype of  npl zebrafish 
morphants via administering ManNAc.
In mammals, activity of  N-acetylneuraminate lyase has been detected in different tissues including 
liver, kidney, spleen, brain, lungs, and erythrocytes, but its biological function remained unclear. Our in 
vitro and in vivo experimental data strongly support the conclusion that the biallelic NPL variants, p.Arg-
63Cys and p.Asn45Asp, are pathogenic and responsible for the biochemical and clinical phenotype of  the 
patients. First, both NPL proteins carrying either p.Arg63Cys or p.Asn45Asp substitution expressed in 
cultured human HEK293T cells had significantly reduced enzymatic NPL activity against Neu5Ac (~6% 
or ~30% of  the WT, respectively). NPL activity in the patient’s RBCs was below the detectable level and 
the Neu5Ac levels were approximately 50- to 100-fold increased as compared with healthy controls, con-
firming that the mutations disrupt in vivo NPL activity and sialic acid catabolism. On the other hand, the 
low-to-undetectable NPL activity in control human fibroblasts suggests variable tissue NPL expression and 
tissue-specific demands for sialic acid catabolism. Second, knockdown of  the npl gene in developing zebraf-
ish embryos showed skeletal myopathy and cardiac edema, which could be rescued by human WT NPL 
mRNA but not by mutants. The cardiac phenotype that we observed in npl morphants is not surprising, 
as many genes involved in human and mouse cardiovascular function and development were previously 
knocked down in zebrafish resulting in cardiac edema and/or looping defect phenotypes (20). Importantly, 
such phenotypes can be rescued by pharmacological intervention with existing drugs (21).
Three signature parts of  the NPL enzyme are sequences located in amino acid regions 42–63, 79–97, 
and 138–155 (http://www.ebi.ac.uk/interpro/protein/Q9BXD5) and are presumably important for the 
enzymatic activity. The mutations p.Asn45Asp and p.Arg63Cys are both in the first signature region. 
Asparagine 45 is fairly conserved among different species (Figure 1D). The p.Asn45Asp mutation is 
very close to one of  the active-site residues (p.Phe47) and so it may alter their positions, causing the 
reduced activity and affinity for the substrate. Our results showed that substitution of  arginine 63 with 
cysteine significantly reduces the enzymatic activity (Figure 2A). Arginine 63 is highly conserved in 
NPL (Figure 1D) and located in an α-helix in proximity to one of  the dimer interface residues (p.Ser57) 
Figure 6. npl morphants are rescued by injection of human WT but not the mutant NPL mRNA. Lateral views and closeups (boxed areas) of 
embryos with or without skeletal myopathy after injection of (A and C) Cont MO or npl-atg MO alone, or (E) npl-atg MO in combination with WT 
human or (G) (NPL mRNA WT) alone. (I) Embryos coinjected with human NPL mRNA carrying a double mutation (63C + 45D) and npl-atg MO; or (K) 
NPL mRNA MUT (63C + 45D) human NPL mRNA; or (M) human NPL mRNA with a single mutation for 63C (MUT 63C) and npl-atg MO; or (Q) 45D 
(MUT 45D) and npl-atg MO; or (O and S) a single mutation (63C or 45D). Closeups (boxed areas) show somites (arrows). Scale bar: 750 μm. (B, D, F, 
H, J, L, N, P, R, T) Confocal images of muscle fibers in somites (arrows) immunostained for phalloidin on 48-hpf embryos. Scale bar: 50 μm. The 
experiment was repeated at least 3 times.
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(http://www.ebi.ac.uk/interpro/protein/Q9BXD5). Substitution of  a positively charged amino acid 
(arginine) that has a long side chain, with the smaller neutral cysteine residue could destabilize the α-he-
lical structure (22). On the other hand, this mutation could potentially perturb the interaction between 
the subunits and hence the quaternary structure of  the enzyme important for activity and stability.
In bacteria, NPL has been extensively studied and was thought to play an important role in controlling 
the intracellular concentration of  sialic acid (7, 23, 24) to prevent the buildup of  its toxic levels and/or as a 
source for energy production. In humans, an additional role of  NPL could be to control the levels of  CMP-
Neu5Ac for protein sialylation, which is not present in most bacteria.
In the process of  cell aging, NPL was proposed to eliminate the excess Neu5Ac generated. In addi-
tion, human NPL can catabolize exogenous Neu5Gc (25). This form of  sialic acid is predominant in 
animals, but cannot be synthesized by humans due to the lack of  CMP-Neu5Gc hydroxylase (CMAH). 
Large amounts of  Neu5Gc are, however, consumed with dairy and meat products and are incorporated 
into glycoproteins that can cause an autoimmune response. Interestingly, both mutations in the reported 
patient completely abolish the enzymatic activity against Neu5Gc, suggesting that NPL deficiency could 
potentially result in its increased incorporation into protein glycans.
Increased Neu5Ac levels are associated with 2 other forms of  free sialic aciduria with a con-
siderably different clinical phenotype. Mutations in the lysosomal sialic acid transporter encoded by 
SLC17A5 result in lysosomal accumulation of  free sialic acid and cause either a severe infantile sialic 
acid storage disease (ISSD) or a slowly progressing juvenile Salla disease. The main clinical symptoms 
in the patients are hypotonia, cerebellar ataxia, and intellectual disability; visceromegaly and coarse 
features are also present in the infantile cases. Cardiomegaly has also been reported (26). The loss 
of  feedback control of  GNE epimerase activity by CMP-NeuAc due to a mutation at the enzyme’s 
allosteric site results in uncontrolled production of  sialic acid and autosomal dominant French-
type sialuria. Only 7 patients so far have been reported in the literature (27). The disorder is perhaps 
Figure 7. Percentage of npl morphants rescued by injection of human WT but not mutant NPL mRNA. Percent-
age of embryos with or without skeletal myopathy obtained after injection of Cont MO or npl-atg MO alone, or 
npl-atg MO in combination with WT human (NPL mRNA WT), or mutant [NPL mRNA MUT (63C + 45D)] human 
NPL mRNA, or human NPL mRNA with a single mutation for 63C (MUT 63C), or 45D (MUT 45D). Bars represent 
the mean ± SD of 4 independent injections; 10 groups were preselected for comparison. Statistical significance 
determined by 2-tailed Student’s t test with Bonferroni’s correction with a factor of 10 using GraphPad Prism 
software version 7. *P < 0.05, **P < 0.01; ns, not significant. For simplicity, only comparisons to the npl-atg MO 
abnormal muscle group are represented in the graph. Each bar represents between 50 and 135 embryos. The 
experiment was repeated 4 times.
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underdiagnosed, as patients have relatively mild phenotype. The fact that French-type sialuria does not 
present with skeletal muscle involvement or cardiomyopathy with a much higher increase of  sialic acid 
as compared with NPL deficiency is not supportive of  the hypothesis that cytosolic accumulation of  
sialic acid itself  leads to the NPL phenotype.
Our data suggest that the disease in NPL-deficient patients is triggered by changes in the cytosolic 
levels of  downstream Neu5Ac metabolites, primarily ManNAc and GlcNAc. The skeletal myopathy in 
npl-morphant zebrafish was rescued by ManNAc, the direct downstream metabolite of  NPL, and to a 
lesser extent by GlcNAc and Neu5Ac. In contrast, rescue of  the heart phenotype was only possible with 
ManNAc. It has been shown that ManNAc can be converted to GlcNAc-6-phosphate, likely via subse-
quent action of  RENBP and GlcNAc kinase. This compound could be metabolized further to gener-
ate fructose-6-phosphate (Fru-6-phosphate) or to generate UDP-GlcNAc, the precursor for glycosylation 
reactions. In analogy to the role of  bacterial NPL in energy production, Fru-6-phosphate could enter gly-
colysis for production of  ATP. The lower efficiency of  GlcNAc in rescuing the npl-knockdown phenotype, 
especially the heart phenotype, does not seem to match this hypothesis. However, the difference in the 
action of  GlcNAc and ManNAc could be related to specifics of  their uptake and transport. In addition, no 
other metabolic pathways are known to act directly on ManNAc. It is also noted that the best 2 rescuing 
monosaccharide compounds ManNAc and GlcNAc are uncharged, but Neu5Ac is negatively charged. 
Thus, Neu5Ac may enter embryos and cells less efficiently than the other sugars. Irrespective of  the mech-
anism, our data imply a clear potential for the use of  these monosaccharides as a novel treatment strategy.
Interestingly, ManNAc and Neu5Ac have also been proposed as treatment for GNE myopathy (28). Over 
100 mutations have been reported in GNE, encoding UDP-N-acetylglucosamine-2-epimerase/N-acetylman-
nosamine kinase, resulting in an adult-onset progressive myopathy with a characteristic pattern of  affected 
muscles; although the hamstring and tibialis anterior muscles are affected severely by early adulthood, the 
quadriceps muscles are spared even at a late stage of  the disorder (28). Cardiac involvement has been report-
ed in GNE myopathy, although sporadically (29). Reduced protein sialylation has been reported in several 
studies. In the mouse model of  the disease, muscle loss was prevented by treating animals with Neu5Ac or 
ManNAc. ManNAc was proposed to increase the synthesis of  Neu5Ac via phosphorylation by a hexNAc 
kinase and subsequent action of  NANS and NANP. This will increase CMP-Neu5Ac levels to improve pro-
tein sialylation. Since ManNAc also rescues the muscle myopathy caused by NPL deficiency in our zebrafish 
model, it is tempting to speculate that overlapping biochemical mechanisms may be involved in both diseases.
Skeletal muscles continually produce low levels of  ROS due to their contractile activity and high 
oxygen consumption and metabolic rate. However, under normal conditions, multiple antioxidant sys-
tems help to keep ROS levels in check and maintain redox homeostasis (30). Recent studies show that 
dysregulated redox homeostasis has emerged as a key pathogenic condition in several muscle diseases 
like muscular dystrophy, GNE myopathy, and other early-onset myopathies (19, 30). Here we show that 
NPL myopathy is also associated with dysregulated ROS production. However, since ROS levels could 
be restored by ManNAc, we believe that enhanced ROS production in NPL myopathy is more likely 
caused by tissue responses to the primary pathology, in contrast with GNE myopathy where enhanced 
ROS is believed to be upstream of  muscle atrophy.
Altogether, our data demonstrate an important biological role of  NPL in cardiac and skeletal muscle 
function, and suggest that a reduced level of  its downstream metabolite ManNAc is the cause of  the cardi-
ac and skeletal muscle phenotype. The results also suggest that supplementation with the commonly used 
dietary sugar GlcNAc could be explored as a potential therapeutic approach for treatment of  NPL deficien-
cy. More research is required to reveal the exact pathological mechanism of  the myopathic phenotype, the 
intrafamilial variability in penetrance, and therapeutic strategies, which will also yield novel insights into 
understanding and treatment of  other glycosylation-related myopathies.
Figure 8. Myopathy in npl morphants is partially rescued by monosaccharide replacement. (A–F) Lateral views of embryos injected with Cont MO or npl-
atg MO. Embryos were incubated with 800 μM of the following monosaccharides: N-acetyl-D-mannosamine (ManNAc), N-acetyl-D-glucosamine (GlcNAc), 
sialic acid, D-galactose, D-mannose, or D-xylose, which were added to the water 2 hours after morpholino injection and incubated for 48 hours. Scale bar: 
750 μm. Closeups of boxed areas show somites (arrows). (G) Percentage of embryos with or without skeletal myopathy obtained after injection with Cont 
MO or npl-atg MO and treatment with ManNAc, GlcNAc, sialic acid, D-galactose, D-mannose, or D-xylose. Bars represent the mean ± SD of 4 independent 
injections. Significance was determined using a 2-tailed t test assuming equal variance data. *P < 0.05. All comparisons were against npl-atg MO normal 
muscle group. Between 25 and 180 embryos were analyzed per condition in 3 independent experiments.
 
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.122373
R E S E A R C H  A R T I C L E
Methods
Human samples. Skin fibroblasts were obtained with informed consent from the patients (P1.1 and P1.2) 
and healthy controls and cultured at 37.0°C under 5.0% CO2 in E199 culture medium, supplemented with 
10% fetal calf  serum and 1% penicillin/streptomycin. All cultures were negative for mycoplasma infection.
WES. The family was enrolled into the TIDEX gene discovery project (University of  British Columbia 
IRB approval H12-00067), and provided written consent for the publication of  this case report. WES of  
the subject and his unaffected parents was performed using the Agilent SureSelect Kit and Illumina HiSeq 
2000 (PerkinElmer), covering 37.8× for the subject, 30.4× for the mother, and 27.5× for the father. The 
sequencing reads were mapped to the hg19 human reference genome. Rare variants, identified as those with 
minor allele frequency (<0.01), were assessed for predicted impact on protein function and screened under 
multiple inheritance models, as described previously (31). Sanger sequencing was performed to confirm 
segregation with disease.
Analysis of  free Neu5Ac levels. Levels of  urinary sialic acids were determined by tandem mass spectrom-
etry as reported previously (32, 33). Fibroblast pellets (~2.5 million cells, obtained after trypsinization) in 
250 μl of  50 mM Tris/HCl (pH 7.5) were sonicated on ice (3 times 8 seconds), and then centrifuged for 10 
minutes at 10,000 g and 4°C. RBCs, washed in 0.9% NaCl, were sonicated on ice (3 times 8 seconds), and 
then centrifuged for 10 minutes at 10,000 g and 4°C. To 100 μl of  the supernatant, 13C3-N-acetyl-neuraminic 
acid (50 μl, Merck) was added as internal standard and the solution was filtered using a 30-kDa filter 
Figure 9. Monosaccharide replacement partially rescues skeletal but not cardiac myopathy in npl morphants. (A–D) 
Confocal images of muscle fibers in somites immunostained for phalloidin on 48-hpf embryos that were injected with 
Cont MO or npl-atg MO. Embryos were incubated with 800 μM of the following monosaccharides: ManNAc, GlcNAc, or 
sialic acid, which were added to the water 2 hours after morpholino injection and incubated for 48 hours. Left panels 
show epifluorescence images of the heart in cmlc2:GFP transgenics at 48 hpf. Between 3 and 5 embryos were analyzed 
per condition in 3 independent experiments. Scale bars: 50 μm (left) and 25 μm (right).
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(Amicon Ultra) into tubes containing 10 μl of  2% formic acid. After centrifugation (30 minutes for fibro-
blasts, 40 minutes for RBCs) at 13,000 g and 4°C, the flow-through was used for quantification of  Neu5Ac 
by mass spectrometry as described previously (1, 2). Assays were performed in duplicate and Neu5Ac levels 
were normalized for protein level in the lysates.
NPL activity in human cells. The lysates of  cultured fibroblasts and RBCs obtained as described above 
were used for protein determination and enzyme activity assay. Ten microliters of  a 5 mM solution of  
Neu5Ac (Carbosynth), 50 μl of  cell lysate, and 30 μl of  50 mM Tris/HCl buffer (pH 7.5) were mixed and 
incubated at 37°C. The reactions were stopped by freezing at –20°C. The samples (100 μl) were then sup-
plemented with 50 μl of  13C3-N-acetyl-neuraminic acid (Merck) as internal standard and the Neu5Ac levels 
were quantified by mass spectrometry as described above.
Analysis of  NPL metabolites in patient cells. Analysis of  NPL metabolites was performed based on pre-
viously described methods with minor modification (17). Briefly, to extract metabolites from RBCs, 35 
μl of  cell homogenate was incubated with 1,400 μl extraction buffer (2:2:1 acetonitrile/methanol/water 
[v/v/v]) for 5 minutes at –20°C. Fibroblasts were seeded in 6-well plates and upon reaching 70% conflu-
ence were washed twice with 75 mM ammonium carbonate buffer (pH 7.4), followed by snap freezing 
in liquid nitrogen. To extract metabolites, wells were incubated twice with 700 μl extraction buffer for 2 
and 3 minutes, respectively, at –20°C. All samples were centrifuged at 16,000 g for 3 minutes followed 
by drying of  the supernatant in a vacuum centrifuge at room temperature. Samples were dissolved in 
50 μl (RBCs) or 100 μl (fibroblasts) LC/MS-grade water. Samples were analyzed using reverse-phase 
ion pairing chromatography (Agilent Technologies 1290 Infinity) coupled to a triple-quadrupole mass 
spectrometer operating in negative ion mode (Agilent Technologies 6490 Triple Quad LC/MS). Metab-
olites were separated on an Acquity UPLC column (Waters, HSS T3 1.8 μm, 2.1 × 150 mm) using a 
gradient of  solvent A (10 mM tributylamine in water) and solvent B (10 mM tributylamine acid in 
methanol). Flow rate was 0.25 ml/min and injection volume was 2 μl. Temperatures of  the autosampler 
and column compartment were kept stable at 7°C and 35°C, respectively. Metabolites were analyzed 
using the following MRM transitions: HexNAc (220.1→119.0 m/z), ManNAc-6P (300.1→78.9 m/z), 
and Neu5Ac (308.1→87.0 m/z).
Expression and functional analysis of  NPL mutant variants in HEK293T cells. Plasmids expressing NPL mutant 
variants were constructed using a QuikChange Lightning kit (Stratagene) with pcDNA3.1+/NPL-C-(K)DYK 
plasmid (OHu08401, GenScript) expressing human DYK-tagged NPL as a matrix. The mutagenesis primers 
were designed using the QuikChange Primer Design Program (http://www.stratagene.com/qcprimerdesign). 
Figure 10. Roles of NPL in sialic acid catabolism and potential monosaccharide replacement therapy. Neu5Ac homeo-
stasis is known to involve a biosynthetic pathway (1) starting from UDP-GlcNAc and a salvage pathway (2) in which 
Neu5Ac released from glycoproteins and glycolipids in the lysosome can be used for CMP-Neu5Ac synthesis. Our data 
lead us to hypothesize that Neu5Ac catabolism also has physiological relevance in this homeostasis and its down-
stream metabolites are important for muscle function.
 
1 7insight.jci.org   https://doi.org/10.1172/jci.insight.122373
R E S E A R C H  A R T I C L E
HEK293T cells (ATCC) were cultured in DMEM supplemented with 10% (v/v) fetal calf  serum (Wisent). 
Transfections were carried out using Lipofectamine LTX (Invitrogen) as described in the manufacturer’s pro-
tocol. Forty-eight hours after transfection, cells were washed with ice-cold PBS, and homogenized in H2O by 
sonication. To study NPL protein stability, 48 hours after transfection cells were washed with PBS and incubat-
ed for 2, 4, 6, 18, and 24 hours in DMEM with 10 % (v/v) fetal calf  serum and 7 μM cycloheximide to inhibit 
de novo protein synthesis. After incubation, cells were washed in PBS, harvested, and stored at –20°C until all 
time points were collected. Cell pellets were resuspended in 200 μl of  RIPA buffer (50 mM Tris HCl, 150 mM 
NaCl, 1% Nonidet P-40, 0.25% Na-deoxycholate, 0.1% SDS, 2 mM EDTA, 1 mM PMSF), supplemented with 
protease and phosphatase inhibitor cocktail (Roche), sonicated for 2 times 10 seconds and cleared by centrifu-
gation at 13,000 g for 10 minutes. The protein was quantified using the Bradford reagent (Bio-Rad).
NPL enzymatic activity in cultured cells or fish embryos was measured against Neu5Ac (Sigma-Al-
drich), Neu5Gc (Sigma-Aldrich), or KDN (provided by A.J. Bennet, Simon Fraser University, Burnaby, 
B.C., Canada) as described by Brunetti et al. (15). The concentration of  the product, ManNAc, was deter-
mined as described by Reissig et al. (34). N-acetyltransferase enzymatic activity was measured using the 
fluorogenic substrate 4-methylumbelliferyl β-D-glucosaminide (4MU-βGlcN, Moscerdam), as previously 
described by He et al. (35).
For Western blot after separation by SDS-PAGE on an 8% gel, the proteins were transferred to a 
nitrocellulose membrane and hybridized with monoclonal rat antibodies against the DYK tag (637301, 
BioLegend, 1:5,000), rabbit polyclonal anti-HGSNAT antibodies (HPA029578, Sigma-Aldrich, 1:1,000), 
or monoclonal mouse anti–β-actin antibodies (47778, Santa Cruz Biotechnology, 1:1,000) followed by 
HPR-conjugated secondary antibodies (7077, 1:8,000 or 7074, 1:10,000; both Cell Signaling Technology). 
The membrane was developed with Pierce ECL Western Blotting substrate (Thermo Fisher Scientific) and 
the signal detected using the G:Box Chemi XQR system (Syngene). The intensities of  bands were quanti-
fied using ImageJ software (NIH).
Zebrafish husbandry. Zebrafish embryos of  the WT and cmlc2:GFP lines were maintained at 28.5°C 
with a cycle of  10 hours/14 hours.
Zebrafish morpholino gene knockdown. To knock down npl gene expression, we used npl-atg MO and npl-sp 
MO and a standard control MO (Cont MO). The MO sequences are as follows: npl-atg MO 5′-CGCGTT-
GAGACATTTCTTCCTTTCA-3′, npl-sp MO 5′-ATGTGCTTTAACTCACTTGCCCTTT-3′, and Cont 
MO 5′-CCTCTTACCTCAGTTACAATTTATA-3′.
MOs were designed by Gene Tools, LLC. Both MOs were injected individually and in combination 
into 1-cell-stage zebrafish embryos. npl-atg (8 ng/μl) and npl-sp (8 ng/μl) MOs were injected individually 
and each injection was repeated at least 3 times.
Knockdown confirmation by RT-PCR. Knockdown of  npl by npl-sp was confirmed by RT-PCR. Embry-
os were injected at the 1-cell stage with 8 ng/μl of  each MO diluted in water (RNAse, DNAse free) 
containing phenol red (Sigma-Aldrich). Two hours after the injection, the embryos were sorted and 
those that incorporated phenol red in the animal pole were selected. At 24 hpf, embryos were manually 
dechorionated. Total RNA was extracted from embryos at 48 hpf  using TRIzol (Invitrogen). The RNA 
concentration of  each sample was quantified using a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies). RNA integrity and band expected were verified using 1% agarose gel electrophore-
sis. The RNA template was converted into cDNA using Superscript II reverse transcriptase (Invitrogen). 
The primers used are as follows: npl forward 5′-CAGCTACATTCACTCCACTCAC-3′ and npl reverse 
3′-CATGCCGAGCCAGTTCTT-5′.
In situ hybridization. RNA in situ hybridization in zebrafish embryos was performed as described previ-
ously (36). Zebrafish npl antisense and sense probes were generated by PCR using template cDNA obtained 
from RNA of  zebrafish embryos at 48 hpf. PCR was used to produce copies of  the transcript ENS-
DART00000011258 (npl). This PCR product was used to amplify a second product containing the T3 and 
T7 promoters in the 5′ and 3′ end, respectively. The riboprobe generated corresponds to 351 bp of  ensemble 
transcript ID. npl transcripts were PCR amplified targeting the transcript ENSDART00000011258. The 
primers used for amplification and the primers amplifying the T3 and T7 promoter containing products 
are as follows: npl forward 5′-CGAGAGGGAGATTCCATCATTT-3′, npl reverse 3′-CCCATTGGTAAC-
CCTGATACTT-5′, npl T7 forward 5′-TAATACGACTCACTATAGGGAAAAGAGAAACGAGAG-
GGAGATTCCATCATTT-3′, and npl T3 reverse 3′-ATTAACCCTCACTAAAGGAAAAGGAGGC-
CCATTGGTAACC CTGATACTT-5′.
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RNA in situ hybridization in zebrafish embryos was performed as described previously (37). All in situ 
hybridization experiments were repeated at least 3 times for each probe and stage.
Western blotting. Larvae injected with Cont MO and npl-atg MO at 3 days after injection (20 larvae/
group) were homogenized in 50 mM Tris buffer (pH 7.5) containing protease inhibitor (Protease Inhib-
itor Cocktail Tablets, Roche). Protein concentration was measured using the bicinchoninic acid (BCA) 
method with bovine serum albumin (BSA) as the standard. Total protein (40 μg) was separated in 10% 
SDS-PAGE, transferred to nitrocellulose membranes, and hybridized with anti-NPL rabbit polyclonal 
antibody (Abcam, catalog ab139057, 1:250 dilution) followed by HRP-labeled anti-rabbit secondary anti-
body (Santa Cruz Biotechnology; 1:3,000 dilution). Protein bands were identified with ECL detection 
and imaged using Image Lab detection system (Bio-Rad). Protein band intensity was quantified using 
ImageJ software. Equal loading was confirmed by incubation of  membranes with Cy3-conjugated mono-
clonal mouse β-actin antibody (Sigma-Aldrich, catalog C5838, 1:1,000) for 1 hour at room temperature.
MO injection and rescue experiments. Human NPL mRNA was obtained using the mMessage mMachine 
T7 kit (Ambion) from the clone U7323BE160-1 in the pcDNA3.1+/C-(K)DYK vector (GenScript). The 
same vector was used to create human NPL mutations pAsn45Asp and pArg63Cys and mutant NPL 
mRNA was synthesized using the same protocol (Ambion). Zebrafish embryos at the 1-cell stage were 
coinjected with 4 ng of  npl-atg MO and 50 pg of NPL mRNA WT and 4 ng of  npl-atg MO and 50 pg of  
human NPL mRNA with double mutation in 63C and 45D (MUT 63C + 45D), or single mutations (NPL 
mRNA MUT 63C), (NPL mRNA MUT 45D).
Zebrafish embryo immunofluorescence. Whole-mount immunofluorescence in zebrafish was performed as 
described below, zebrafish embryos at 48 hpf  were fixed with 4% paraformaldehyde (PFA) overnight at 
4°C. After fixation, 5 washes were conducted in PBS. All reactions were performed at room temperature 
(with gentle shaking) by sequential incubations in the following order: 10% normal goat serum (NGS), 1% 
BSA in PBS for 2 hours; washed 3 times 5 minutes each in PBST; then fluorescent (Alexa Fluor 488) phal-
loidin, diluted 1:1,000, for 2 hours. After three 15-minute washes in PBS, zebrafish embryos were mounted 
between 2 coverslips separated by petroleum jelly grease, in fresh mounting medium.
Zebrafish larva locomotion behavior assay. Zebrafish larvae at 2 dpf  were placed in individual wells of  
a 12-well plate in embryo medium (E2) and placed in a Zebrabox (ViewPoint Life Sciences) for video 
recording. The larvae were lightly touched with the tip of  an Eppendorf  Microloader and the behavior was 
recorded using the equipped camera at a frame rate of  30 Hz. The locomotor behavior was then analyzed 
using the manual tracking plugin of  ImageJ, and the total distance swam, maximum velocity, and swim 
duration of  each larva were calculated. Each zebrafish larva was touched 10 times in order to determine its 
escape response behavior. For each condition, a sample size of  6–9 larvae was used to determine the mean 
and standard deviation of  the behavior responses.
Zebrafish assay for oxidative stress. ROS levels in zebrafish larvae were visualized using the ROS indicator 
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA; Sigma-Aldrich), as previously described (37). Brief-
ly, embryos were injected at the 1-cell stage with Cont MO, npl-atg MO, or npl-atg MO plus WT human 
NPL mRNA. Some of  the embryos injected with the npl-atg MO were then incubated with ManNAc (800 
μM) 2 hours after injection. At 2 dpf, all the embryos were incubated with 100 μM DCFH-DA for 1 hour at 
28.5°C in the dark, and washed 3 times for 5 minutes each with embryo water. Images were acquired using 
a Leica DFC 300-FX camera and a Leica fluorescence microscope, and were processed with Fiji analysis 
software. Corrected total fluorescence (CTF) was calculated using the following formula: CTF = integrated 
density – (area of  selected cell × mean fluorescence of  background readings). For each experimental group, 
n = 10–11 fish per treatment. The experiment was repeated 2 times.
Microscopy. Live embryos were imaged in bright field and epifluorescence mode using fluorescent dis-
section microscopy (Leica M205 FA); fixed samples were imaged using confocal microscopy with a Zeiss 
laser-scanning microscope (LSM 700). Live embryos were anesthetized using 0.16 mg/ml tricaine meth-
anesulfonate (Sigma-Aldrich) and embedded in 2.5% methylcellulose (Sigma-Aldrich). Embryos fixed with 
4% PFA were embedded in 1% low-melting-temperature agarose (BioShop). Images were analyzed with 
LSM software (Zeiss), LAS FA software (Leica), Photoshop CS3 (Adobe), and ImageJ.
Statistics. Student’s t tests and 1-way ANOVA with appropriate post hoc tests were performed using 
GraphPad Prism software version 7 for statistical analyses and detailed test information is indicated 
in the figure legends. A linear mixed-effects model was used for the zebrafish larva locomotor behav-
ior assay, with npl MO injection conditions (fixed effect) and individual larvae (random effect) with 
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Bonferroni’s post hoc test, using the R statistical package (https://www.r-project.org/). P < 0.05 was 
considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Study approval. All zebrafish studies were approved by the Animal Care Committee of  St. Michael’s 
Hospital under the protocol number ACC660. TIDEX gene discovery study was approved by the Universi-
ty of  British Columbia Research Ethics Board (IRB H12-00067).
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